Debashis Pal

Mr. Debashis Pal

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in European Economic Review
Verified
Journal Article
Closed access
ABArup Bose
Arup Bose
DPDebashis Pal
Debashis Pal
DSDavid E.M. Sappington
David E.M. Sappington

4 March 2022 in Hemoglobin
Verified
Journal Article
Closed access
DSDipankar Saha
Dipankar Saha
PCProsanto Kr. Chowdhury
Prosanto Kr. Chowdhury
APAmrita Panja
Amrita Panja
DPDebashis Pal
Debashis Pal
KNKaustav Nayek
Kaustav Nayek
ABANUPAM BASU
ANUPAM BASU
Thalassemia is the most common inherited hemoglobinopathy worldwide. Variation of clinical symptoms in this hemoglobinopathy entails differences in disease-onset and transfusion requirements. The aim of this study was to investigate the role of α-globin gene deletions in modulating the clinical heterogeneity of β-thalassemia (β-thal) syndromes. A total number 270 β-thal subjects were enrolled. Hematological parameters were recorded. β-Globin mutations were determined by amplified refractory mutation system-polymerase chain reaction (ARMS-PCR), gap-PCR and Sanger sequencing. α-Globin gene deletions were determined by multiplex PCR. Out of 270 β-thal subjects, 19 carried β+/β+, 74 had β0/β0 and 177 had the β0/β+ genotype. When we determined the severity of the different β-thal subjects in coinherited with the α gene deletion, it was revealed that, 84.2% β+/β+ subjects carried a non severe phenotype and did not have an α gene deletion. Of the β0/β0 individuals, 95.9% presented a severe phenotype, irrespective of α-globin gene deletions. In cases with the β0/β+ genotype, 19.2% subjects also carried a deletion on the α gene. Of these, 61.8% presented a non severe phenotype and 38.2% were severely affected. Only in the β0/β+ category did α gene deletions make a significant contribution (p < 0.001) toward alleviation of clinical severity. Therefore, it can be stated that α-globin gene deletions play a role in ameliorating the phenotype in patients with a β+/β0 genotype.

16 January 2025 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
DPDebashis Pal
Debashis Pal
PCProsanto Kumar Chowdhury
Prosanto Kumar Chowdhury
KNKaustav Nayek
Kaustav Nayek
NBNidhan K. Biswas
Nidhan K. Biswas
SDSubrata Das
Subrata Das
ABANUPAM BASU
ANUPAM BASU

29 January 2026 in Thalassemia Reports
Verified
Journal Article
Open access
PDF file
DPDebashis Pal
Debashis Pal
DSDipankar Saha
Dipankar Saha
Prosanto Kumar ChowdhuryProsanto Kumar Chowdhury
Prosanto Kumar Chowdhury
ADArup Das
Arup Das
ABANUPAM BASU
ANUPAM BASU
β-thalassemia patients often experience ocular abnormalities such as angioid streaks (ASs), retinal pigmented epithelium degradation, visual field defects, and in rare instances choroidal neovascularization (CNV). Although ASs are common in individuals with hemoglobinopathies, the occurrence of choroidal neovascularization without preceding ASs is exceptionally rare. In this report, we describe a β-thalassemia patient who had developed CNV at the age of 27 years and also had experience of renal stones at the age of 19 years. He had undergone splenectomy and was under conservative therapy of iron supplementation. We conducted whole-exome sequencing (WES) in search of CNV-associated variants. Through variant filtering and Phenolyzer analysis, we have identified a rare heterozygous missense variant in the ABCC6 gene, ABCC6:NM_001171:exon25:c.3524T>C (rs376062004). In silico analysis revealed that this variant is present in the highly conserved region and is likely to decrease the stability of the protein. Mutation in the ABCC6 gene leads to pseudoxanthoma elasticum (PXE). Previously, it was believed that ASs and subsequent CNV-like ocular complication may develop due to the pathophysiological condition of thalassemia. However, our study provides compelling evidence that rare mutations in the ABCC6 gene, in combination with oxygen insufficiency, may contribute to the development of CNV in β-thalassemia patients. This finding highlights the potential genetic basis of PXE-mediated CNV development in β-thalassemia.

3 January 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
DSDipankar Saha
Dipankar Saha
DPDebashis Pal
Debashis Pal
Prosanto Kumar ChowdhuryProsanto Kumar Chowdhury
Prosanto Kumar Chowdhury
KNKaustav Nayek
Kaustav Nayek
GCGispati Chakraborty
Gispati Chakraborty
ABANUPAM BASU
ANUPAM BASU
Thalassemia is a common monogenic autosomal disorder prevalent in India. HbE beta thalassemia is a compound heterozygous state of two different beta globin mutations (HBB), predominant in the Eastern India. In HbE-beta thalassemia (β+/β°) patients, one HBB mutation does not produce any functional protein (β°); another mutation produces a structural altered haemoglobin, variant E (β+). It has been observed that in HbE-beta thalassemia patients with same type of HBB mutations, there exist diverse phenotypic presentation ranging from very severe, with regular transfusion-dependence to clinically non severe requiring very less transfusion or no transfusion. To explore this phenotypic mystery, we performed trio based expanded whole exome sequencing (WES) of two extreme phenotypes of HbE beta thalassemia subjects with similar HBB genotype and their parents. For WES library preparation, Agilent Sure select V6+UTR kit was used and sequencing was done through the Illumina HiSeq 2500 platform. This study aimed to search for de novo or inherited variants associated with the clinical severity. Six significant inherited variants were found in the genes, ATOH8, TTLL4, P2RX7, PRSS54, SLC9C2 and VRK2 in severe subject, however only one significant inherited variant in MTRR gene was found in non-severe subject. Bioinformatic analysis also confirms that each variant significantly changes in respective protein structure. The identified genes were either associated with iron absorption, oxidative stress, hematopoietic stem cell differentiation, structural organization of RBC cytoskeleton or regulating anemia. No significant de novo variant were identified associated with clinical severity. The finding of this study indicates that the combined effect of mutation load in major pathways may responsible for severe phenotype.